Recent news on Luveris

Phase III Data on Safinamide in Parkinson's Disease Presented at ...  -  May 2, 2007
PipelineReview.com (press release),The Company is the world leader in reproductive health, with Gonal-f(R), Luveris(R)and Ovidrel(R)/Ovitrelle(R). It has strong market positions in neurology,

Merck Serono SA to Voluntarily Delist and Deregister its Bearer ...  -  Apr 6, 2007
Drug Newswire (press release),The Company is the world leader in reproductive health, with Gonal-f(R), Luveris(R) and Ovidrel(R)/Ovitrelle(R). It has strong market positions in neurology

Merck KGaA Announces Serono Preliminary Figures for 2006  -  Mar 23, 2007
Drug Newswire (press release),The Company is the world leader in reproductive health, with Gonal-f(R), Luveris(R) and Ovidrel(R)/Ovitrelle(R). It has strong market positions in neurology

Merck Serono Launches easypod(R), First Electronic Growth Hormone ...  -  Jan 30, 2007
Drug Newswire (press release),The Company is the world leader in reproductive health, with Gonal-f(R), Luveris(R) and Ovidrel(R)/Ovitrelle(R). It has strong market positions in neurology

Merck Serono Launches easypod(R), First Electronic Growth Hormone ...  -  Jan 29, 2007
Yahoo! News (press release)The Company is the world leader in reproductive health, with Gonal-f®, Luveris® and Ovidrel®/Ovitrelle®. It has strong market positions in neurology,

Merck Serono Completes Patient Enrollment in CLARITY Phase III ...  -  Jan 16, 2007
Drug Newswire (press release),The Company is the world leader in reproductive health, with Gonal-f(R), Luveris(R) and Ovidrel(R)/Ovitrelle(R). It has strong market positions in neurology

Merck Serono is Launched  -  Jan 7, 2007
Yahoo! News (press release)The Company is the world leader in reproductive health, with Gonal-f®, Luveris® and Ovidrel®/Ovitrelle®. It has strong market positions in neurology,

Merck KGaA Acquires Majority Shareholding in Serono SA  -  Jan 5, 2007
Genetic Engineering News (press release),The Company has eight biotechnology products, Rebif(R), Gonal-f(R), Luveris(R), Ovidrel(R )/Ovitrelle(R), Serostim(R), Saizen(R), Zorbtive(TM) and

Merck KGaA Acquires Majority Shareholding in Serono SA  -  Jan 5, 2007
Yahoo! News (press release)The Company has eight biotechnology products, Rebif®, Gonal-f®, Luveris®, Ovidrel(R )/Ovitrelle®, Serostim®, Saizen®, Zorbtive(TM) and Raptiva®.

ZymoGenetics and Serono Begin Phase 2 Clinical Trial With ...  -  Dec 19, 2006
PR Newswire (press release),The Company has eight biotechnology products, Rebif(R), Gonal-f(R), Luveris(R), Ovidrel(R)/Ovitrelle(R), Serostim(R), Saizen(R), Zorbtive(TM) and Raptiva(R)

Merck KGaA: European Antitrust Authorities Clear Acquisition of Serono  -  Dec 17, 2006
Yahoo! News (press release)The Company has eight biotechnology products, Rebif®, Gonal-f®, Luveris®, Ovidrel ®/Ovitrelle®, Serostim®, Saizen®, Zorbtive(TM) and Raptiva®.

24-Week Clear Study Results Confirm Sustained Efficacy and Safety ...  Oct 30, 2006
The Company has eight biotechnology products, Rebif(R), Gonal-f(R), Luveris(R), Ovidrel(R) /Ovitrelle(R), Serostim(R), Saizen(R), Zorbtive(TM) and Raptiva(R ... -PR Newswire UK (press release), Serono Delivers Strong Adjusted* Net Income of $183.5m in Third ...  Oct 18, 2006
...m in line with the third quarter of 2005 (Q3 2005: $125.6m). Global sales of supporting products (Ovidrel(R), Cetrotide(R), Crinone(R) and Luveris(R)) were up ... -PR Newswire (press release), 24-Week Clear Study Results Confirm Sustained Efficacy And Safety ...  Oct 31, 2006
The Company has eight biotechnology products, Rebif®, Gonal-f®, Luveris®, Ovidrel®/Ovitrelle®, Serostim®, Saizen®, Zorbtive™ and Raptiva®. ... -PipelineReview.com (press release), Serono and Newron Announce Global Development and ...  Oct 15, 2006
The Company has eight biotechnology products, Rebif(R), Gonal-f(R), Luveris(R), Ovidrel(R )/Ovitrelle(R), Serostim(R), Saizen(R), Zorbtive(TM) and Raptiva(R ... -Earthtimes.org Serono and Newron Announce Global Development and ...  Oct 15, 2006
The Company has eight biotechnology products, Rebif®, Gonal-f®, Luveris®, Ovidrel(R )/Ovitrelle®, Serostim®, Saizen®, Zorbtive(TM) and Raptiva®. ... -Yahoo! News (press release) Serono Delivers Strong Adjusted* Net Income of $183.5m in Third ...  Oct 18, 2006
...m in line with the third quarter of 2005 (Q3 2005: $125.6m). Global sales of supporting products (Ovidrel®, Cetrotide®, Crinone® and Luveris®) were up 11.5 ... -Yahoo! News (press release) Serono Delivers Strong Adjusted* Net Income of $183.5m in Third ...  Oct 18, 2006
...m in line with the third quarter of 2005 (Q3 2005: $125.6m ). Global sales of supporting products (Ovidrel(R), Cetrotide(R), Crinone(R) and Luveris(R)) were up ... -Genetic Engineering News (press release), Merck KgaA to Acquire Serono  Sep 21, 2006
The Company has eight biotechnology products, Rebif®, Gonal-f®, Luveris®, Ovidrel(R )/Ovitrelle®, Serostim®, Saizen®, Zorbtive(TM) and Raptiva®. ... -Yahoo! News

Serono's Oral Cladribine for the Treatment of Multiple Sclerosis ...  Sep 21, 2006
The Company has eight biotechnology products, Rebif(R), Gonal-f(R), Luveris(R), Ovidrel(R )/Ovitrelle(R), Serostim(R), Saizen(R), Zorbtive(TM) and Raptiva(R ... -PharmaLive.com

Serono And Syntonix To Pursue The Development Of A Long-Acting ...  Sep 19, 2006
The Company has eight biotechnology products, Rebif®, Gonal-f®, Luveris®, Ovidrel®/Ovitrelle®, Serostim®, Saizen®, Zorbtive™ and Raptiva®. ... -PipelineReview.com

BioMarin and Serono Announce Data on Phenoptin in PKU to be ...  Sep 12, 2006
The Company has eight biotechnology products, Rebif(R), Gonal-f(R), Luveris(R), Ovidrel(R)/Ovitrelle(R), Serostim(R), Saizen(R), Zorbtive(TM) and Raptiva(R ... -PharmaLive.com

Serono Announces Initiation of the Reflex Trial to Evaluate New ...  -  12 Dec 2006
Drug Newswire (press release),The Company has eight biotechnology products, Rebif(R), Gonal-f(R), Luveris(R), Ovidrel(R) /Ovitrelle(R), Serostim(R), Saizen(R), Zorbtive(TM) and

Serono Announces Results From Pivotal Phase III Clinical Trial of ...  Aug 17, 2006
The Company has seven recombinant products, Rebif(R) (interferon beta-1a), Gonal-f(R) (follitropin alfa for injection), Luveris(R) (lutropin alfa), Ovidrel ... -PR Newswire

Get the latest news direct to your desktop  Aug 18, 2006
The Company has seven recombinant products, Rebif® (interferon beta-1a), Gonal-F® (follitropin alfa for injection), Luveris® (lutropin alfa), Ovidrel ... -PipelineReview.com

Serono Delivers Second Quarter EPS of $12.92, Up 25.2% on Adjusted ...  Jul 26, 2006
Global sales of supporting products (Ovidrel®, Cetrotide®, Crinone® and Luveris®) were up 6.9%, or 7.5% in local currencies to $23.8m (Q2 2005: $22.2m). ... -Yahoo! News

Serono Delivers Second Quarter EPS of $12.92, Up 25.2% on Adjusted ...  Jul 26, 2006
Global sales of supporting products (Ovidrel(R), Cetrotide(R), Crinone(R) and Luveris(R)) were up 6.9%, or 7.5% in local currencies to $23.8m (Q2 2005: $22.2m ... -PR Newswire

European Commission Approves Revision of Therapeutic Indication ...  Jul 9, 2006
The Company has eight biotechnology products, Rebif®, Gonal-f®, Luveris®, Ovidrel® /Ovitrelle®, Serostim®, Saizen®, Zorbtive(TM) and Raptiva®. ... -Yahoo! News

European Commission Approves Revision of Therapeutic Indication ...  Jul 10, 2006
The Company has eight biotechnology products, Rebif(R), Gonal-f(R), Luveris(R), Ovidrel(R) /Ovitrelle(R), Serostim(R), Saizen(R), Zorbtive(TM) and Raptiva(R ... -PharmaLive.com



Rodman & Renshaw 3rd Annual Global Healthcare Conference 2006 ...  May 11, 2006
The Company has eight biotechnology products, Rebif(R), Gonal-f(R), Luveris(R), Ovidrel(R)/ Ovitrelle(R), Serostim(R), Saizen(R), Zorbtive(TM) and Raptiva(R ... - Genetic Engineering News

Serono Announces New Appointments to its Executive Management ...  May 9, 2006
The Company has eight biotechnology products, Rebif(R), Gonal-f(R), Luveris(R), Ovidrel(R )/Ovitrelle(R), Serostim(R), Saizen(R), Zorbtive(TM) and Raptiva(R ... - PharmaLive.com

Serono Announces New Appointments to its Executive Management ...  May 8, 2006
The Company has eight biotechnology products, Rebif®, Gonal-f®, Luveris®, Ovidrel(R )/Ovitrelle®, Serostim®, Saizen®, Zorbtive(TM) and Raptiva®. ... - Yahoo! News

Phase III Trial Of Oral Cladribine, A Novel Investigational ...  May 5, 2006
The Company has seven biotechnology products in the US, Rebif(R) (interferon beta-1a), Gonal-f(R) (follitropin alfa for injection), Luveris(R) (lutropin alfa ... - Medical News Today

Serono Delivers Strong First Quarter 2006 With Revenue Growth of ...  Apr 19, 2006
Global sales of supporting products (Ovidrel®, Cetrotide®, Crinone® and Luveris®) were up 11.3%, or 16.6% in local currencies, to $22.6m. ... - Yahoo! News

Serono Delivers Strong First Quarter 2006 With Revenue Growth of ...  Apr 19, 2006
Global sales of supporting products (Ovidrel(R), Cetrotide(R), Crinone(R) and Luveris(R)) were up 11.3%, or 16.6% in local currencies, to $22.6m. ... - MSN Money

Serono Shareholders Approve Resolutions at Annual General Meeting  Apr 25, 2006
The Company has eight biotechnology products, Rebif®, Gonal-f®, Luveris®, Ovidrel® /Ovitrelle®, Serostim®, Saizen®, Zorbtive(TM) and Raptiva®. ... - Yahoo! News

Serono Shareholders Approve Resolutions at Annual General Meeting  Apr 25, 2006
The Company has eight biotechnology products, Rebif(R), Gonal-f(R), Luveris(R), Ovidrel(R) /Ovitrelle(R), Serostim(R), Saizen(R), Zorbtive(TM) and Raptiva(R ... - PharmaLive.com





Serono Says Its Controlling Shareholder, Bertarelli Family ...  Apr 9, 2006
With its eight biotechnology products such as Rebif, Gonal-f, Luveris, Ovidrel/Ovitrelle, Serostim, Saizen, Zorbtive and Raptiva, Serono achieved worldwide ... - Trading Markets



Seronons 2005 Adjusted(i) EPS Increased by 34.6%  Feb 5, 2006
The Company has eight biotechnology products, Rebif®, Gonal-f®, Luveris®, Ovidrel(R )/Ovitrelle®, Serostim®, Saizen®, Zorbtive(TM) and Raptiva®. ... - Yahoo! News

Seronons 2005 Adjusted(i) EPS Increased by 34.6%  Feb 5, 2006
The Company has eight biotechnology products, Rebif(R), Gonal-f(R), Luveris(R), Ovidrel(R )/Ovitrelle(R), Serostim(R), Saizen(R), Zorbtive(TM) and Raptiva(R ... - MSN Money

Seronons 2005 Adjusted(i) EPS Increased by 34.6%  Feb 5, 2006
The Company has eight biotechnology products, Rebif®, Gonal-f®, Luveris®, Ovidrel(R )/Ovitrelle®, Serostim®, Saizen®, Zorbtive(TM) and Raptiva®. ... - Yahoo! News

Dead kangaroos don’t bounce, do they?  Jan 14, 2006
...development. The company markets eight recombinant products – Rebif, Gonal-f, Saizen, Serostim, Ovidrel, Luveris, Zorbtive and Raptiva. ... - Business Online

Serono Completes Second Phase III Trial of its Proprietary ...  Jan 8, 2006
The Company has eight biotechnology products, Rebif®, Gonal-f®, Luveris®, Ovidrel® /Ovitrelle®, Serostim®, Saizen®, Zorbtive(TM) and Raptiva®. ... - Yahoo! News

Serono Completes Second Phase III Trial of its Proprietary ...  Jan 8, 2006
The Company has eight biotechnology products, Rebif(R), Gonal-f(R), Luveris(R), Ovidrel(R) /Ovitrelle(R), Serostim(R), Saizen(R), Zorbtive(TM) and Raptiva(R ... - PR Newswire

This site is for informational purposes only--it does not offer medical advice or sell health products. If you need assistance, contact your physician or healthcare professional